Analytical Data
-
Gene name
KIR2DL2/CD158b1
- Application
-
Alternative Names
CD158B1; Cl-43; Nkat6; CD158 antigen-like family member B1; Natural killer-associated transcript 6; MHC class I NK cell receptor; p58 natural killer cell receptor clone CL-43
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P43627
-
Expression Region
His22~Glu339
-
Molecular Weight
75kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KIR2DL2, also known as CD158b1, is a key member of the Killer Immunoglobulin-like Receptor (KIR) family, which plays a crucial role in the regulation of natural killer (NK) cell activity. This receptor is expressed on the surface of NK cells and interacts with specific ligands, primarily HLA-C molecules, to modulate immune responses. Understanding the structure and function of KIR2DL2 is important because it can influence the outcome of various immune responses, including those related to viral infections and tumor surveillance. Research into the recombinant protein of KIR2DL2/CD158b1 has gained traction as it provides valuable insights into its binding characteristics, signaling pathways, and potential implications in immunotherapy. By generating and characterizing this recombinant protein, scientists aim to dissect the receptor's mechanisms, identify its ligand affinity, and explore its role in shaping immune responses. This knowledge could pave the way for novel therapeutic strategies targeting KIR2DL2 in diseases where NK cell activity is pertinent, such as cancer and chronic infections. The study of KIR2DL2 as a recombinant protein also holds promise for the development of diagnostic tools and enhancing the efficacy of immunotherapies by optimizing NK cell functionality.
